Trevi Announces License Agreements for use of Nalbuphine for the Treatment of LID in Parkinson’s…
Trevi Therapeutics announced that it had entered into exclusive license agreements with Rutgers, The State University of New Jersey and MentiNova, Inc. for intellectual property and…
Read More...
Read More...
